An open-label pilot phase 2 study to investigate the preliminary efficacy and safety of aldoxorubicin in subjects with unresectable glioblastoma whose tumors have progressed following prior treatment with surgery, radiation and temozolomide

Trial Profile

An open-label pilot phase 2 study to investigate the preliminary efficacy and safety of aldoxorubicin in subjects with unresectable glioblastoma whose tumors have progressed following prior treatment with surgery, radiation and temozolomide

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Aldoxorubicin (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 04 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 17 Aug 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
    • 07 Jun 2016 Results of preliminary efficacy and safety presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top